Belimumab in systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biol...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilas-Boas, Andreia, Morais, Sandra A, Isenberg, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612697/
https://www.ncbi.nlm.nih.gov/pubmed/26509047
http://dx.doi.org/10.1136/rmdopen-2014-000011
_version_ 1782396204802375680
author Vilas-Boas, Andreia
Morais, Sandra A
Isenberg, David A
author_facet Vilas-Boas, Andreia
Morais, Sandra A
Isenberg, David A
author_sort Vilas-Boas, Andreia
collection PubMed
description Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biological drug to be approved for the treatment of SLE in more than 50 years. This monoclonal antibody blocks B-cell activating factor, a cytokine important for B-cell differentiation and survival. In this review we focus on the activity of belimumab in patients with SLE and discuss the controversies of its use.
format Online
Article
Text
id pubmed-4612697
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46126972015-10-27 Belimumab in systemic lupus erythematosus Vilas-Boas, Andreia Morais, Sandra A Isenberg, David A RMD Open Systemic Lupus Erythematosus Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biological drug to be approved for the treatment of SLE in more than 50 years. This monoclonal antibody blocks B-cell activating factor, a cytokine important for B-cell differentiation and survival. In this review we focus on the activity of belimumab in patients with SLE and discuss the controversies of its use. BMJ Publishing Group 2015-03-03 /pmc/articles/PMC4612697/ /pubmed/26509047 http://dx.doi.org/10.1136/rmdopen-2014-000011 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Systemic Lupus Erythematosus
Vilas-Boas, Andreia
Morais, Sandra A
Isenberg, David A
Belimumab in systemic lupus erythematosus
title Belimumab in systemic lupus erythematosus
title_full Belimumab in systemic lupus erythematosus
title_fullStr Belimumab in systemic lupus erythematosus
title_full_unstemmed Belimumab in systemic lupus erythematosus
title_short Belimumab in systemic lupus erythematosus
title_sort belimumab in systemic lupus erythematosus
topic Systemic Lupus Erythematosus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612697/
https://www.ncbi.nlm.nih.gov/pubmed/26509047
http://dx.doi.org/10.1136/rmdopen-2014-000011
work_keys_str_mv AT vilasboasandreia belimumabinsystemiclupuserythematosus
AT moraissandraa belimumabinsystemiclupuserythematosus
AT isenbergdavida belimumabinsystemiclupuserythematosus

Ejemplares similares